ClinicalTrials.Veeva

Menu

Nebulized Dexmedetomidine as a Premedication for Gastrointestinal Endoscopy in Pediatric Patients

O

Ondokuz Mayıs University

Status

Completed

Conditions

Sedation
Pediatric

Treatments

Drug: Nebulized with dexmedetomidine
Other: a routine sedation protocol

Study type

Interventional

Funder types

Other

Identifiers

NCT06218797
NDUGIE2023

Details and patient eligibility

About

This study aims to demonstrate that the application of nebulized dexmedetomidine to patients during pediatric upper gastrointestinal endoscopic procedures will significantly reduce the gag reflex and enhance both patient and practitioner comfort

Full description

Due to the intolerance of pediatric patients to the insertion of the endoscopic probe during upper gastrointestinal procedures, sedation and analgesia are required. In this patient group, the reflex to vomit is common during probe placement. Discomfort, pain, and hemodynamic changes can occur due to the vomiting reflex. In fact, this situation can lead to serious complications such as esophageal rupture. Inappropriate sedation conditions may result in increased post-procedural pain and agitation in patients.

Therefore, various sedative drugs are used for procedural sedation in pediatric patients. The use of these drugs during gastrointestinal endoscopy in the pediatric population can vary in terms of sedative, hemodynamic, respiratory, and side effects.

Dexmedetomidine, a highly selective alpha-2 agonist with central sedative and anxiolytic properties, has been tested in children for preoperative anxiolysis through nasal and inhalation routes. Due to its bioavailability of up to 82%, it is well absorbed systemically through oral and buccal routes.' It possesses sedative, analgesic, sympatholytic, and hemodynamic stability properties. Even at high doses, it has a unique feature of not causing respiratory depression, which gives it an advantage over other sedatives such as benzodiazepines, opioids, and propofol, all of which can cause dose-dependent respiratory depression. In this regard, it may be a good alternative for procedures like gastrointestinal endoscopy.

Based on these considerations, the investigators plan to conduct a randomized controlled study hypothesizing that nebulized dexmedetomidine as premedication in pediatric patients undergoing gastrointestinal endoscopy will significantly reduce the gag reflex.

108 patients will be included in the study. Patients will be divided into 2 groups.

  • The control group (Group C)
  • The group receiving nebulized dexmedetomidine (ND) (Group ND).

Enrollment

108 patients

Sex

All

Ages

2 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • American Society of Anesthesiologists (ASA) physical status I and II
  • 2 to 17 years of age,
  • Patient undergoing in Upper Gastrointestinal Endoscopy

Exclusion criteria

  • Patients with heart disease
  • Patients with mental-motor retardation
  • Patients with abnormal upper respiratory tract
  • Patients with a history of asthma
  • Patients with upper respiratory tract history in the last 4 weeks
  • Patients with severe sleep apnea on polysomnography
  • ASA >III patients
  • Patients with drug allergies

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

108 participants in 2 patient groups

Group C
Active Comparator group
Description:
Control group
Treatment:
Other: a routine sedation protocol
Group ND
Active Comparator group
Description:
Nebulisation with dexmedetomidine
Treatment:
Drug: Nebulized with dexmedetomidine

Trial contacts and locations

1

Loading...

Central trial contact

Esra Turunç, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems